Showing results (1-10 of 42) with videos related to
Sort By:
Pageof 5
Biochemistry|April 9, 1991
Biochemical analysis of the ligand for the neu oncogenic receptorY Yarden, E PelesBioessays : News and Reviews in Molecular, Cellular and Developmental Biology|December 1, 1993
Neu and its ligands: from an oncogene to neural factorsE Peles, Y YardenCurrent Opinion in Neurobiology|November 21, 2000
Molecular domains of myelinated axonsE Peles, J L SalzerTrends in Biochemical Sciences|May 19, 1998
Multi-ligand interactions with receptor-like protein tyrosine phosphatase beta: implications for intercellular signalingE Peles, J Schlessinger, M GrumetBiochemistry|December 18, 1990
Heterodimerization of the erbB-1 and erbB-2 receptors in human breast carcinoma cells: a mechanism for receptor transregulationR Goldman, R B Levy, E Peles, et al.Current Opinion in Neurobiology|May 6, 1998
Cell-contact-dependent signalling in axon growth and guidance: Eph receptor tyrosine kinases and receptor protein tyrosine phosphatase betaS J Holland, E Peles, T Pawson, et al.Harefuah|June 23, 2001
[Traumatic brain injury--the National Trauma Registry]E Peles, V Barell, V Boyko, et al.The Journal of Biological Chemistry|August 25, 1992
An oncogenic point mutation confers high affinity ligand binding to the neu receptor. Implications for the generation of site heterogeneityR Ben-Levy, E Peles, R Goldman-Michael, et al.Oncogene|April 21, 2001
Glial tumor cell adhesion is mediated by binding of the FNIII domain of receptor protein tyrosine phosphatase beta (RPTPbeta) to tenascin CK Adamsky, J Schilling, J Garwood, et al.The EMBO Journal|August 1, 1991
Oncogenic forms of the neu/HER2 tyrosine kinase are permanently coupled to phospholipase C gammaE Peles, R B Levy, E Or, et al.Pageof 5